Literature DB >> 17105175

Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab')2 fragments.

Ville Väisänen1, Mari T Peltola, Hans Lilja, Martti Nurmi, Kim Pettersson.   

Abstract

Various blood constituents can interfere with immunoassays, usually by binding the Fc portion of antibodies. Our previously developed assays for intact free prostate-specific antigen (PSA), free human kallikrein 2 (hK2), and total hK2 frequently yielded falsely high results despite including an excess of scavenger antibodies. We investigated whether this interference could be eliminated by replacing monoclonal capture or tracer antibodies with F(ab')2 or recombinant Fab fragments. Female heparin plasma samples (n = 1092), which should have negligible PSA and hK2, and male samples (n = 957) were analyzed to identify samples manifesting interference, which then were used to optimize protocols for the immunoassays. We compared original assays (monoclonal antibodies) versus optimized assays (F(ab')2 fragments: denatured mouse IgG added as scavenger) using another set of EDTA plasma (n = 113), heparin plasma (n = 160), and serum samples (n = 171). With the original assays, the frequency of falsely elevated hK2 and intact free PSA was 15 and 13%, respectively. The optimized assays eliminated 70-85% of these falsely elevated results and importantly reduced the magnitude in the remainder. F(ab')2 fragmentation was the most important factor in reducing interference. The optimized intact free PSA, free hK2, and total hK2 assays manifested high accuracy close to the lower limit of detection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105175     DOI: 10.1021/ac061201+

Source DB:  PubMed          Journal:  Anal Chem        ISSN: 0003-2700            Impact factor:   6.986


  29 in total

1.  Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Authors:  Tobias Nordström; Andrew Vickers; Melissa Assel; Hans Lilja; Henrik Grönberg; Martin Eklund
Journal:  Eur Urol       Date:  2014-08-20       Impact factor: 20.096

2.  A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.

Authors:  Katharina Braun; Daniel D Sjoberg; Andrew J Vickers; Hans Lilja; Anders S Bjartell
Journal:  Eur Urol       Date:  2015-05-13       Impact factor: 20.096

3.  Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men.

Authors:  Daniel D Sjoberg; Andrew J Vickers; Melissa Assel; Anders Dahlin; Bing Ying Poon; David Ulmert; Hans Lilja
Journal:  Eur Urol       Date:  2018-03-05       Impact factor: 20.096

4.  Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.

Authors:  Pär Stattin; Andrew J Vickers; Daniel D Sjoberg; Robert Johansson; Torvald Granfors; Mattias Johansson; Kim Pettersson; Peter T Scardino; Göran Hallmans; Hans Lilja
Journal:  Eur Urol       Date:  2015-02-11       Impact factor: 20.096

5.  Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men.

Authors:  Melissa J Assel; Hans David Ulmert; R Jeffery Karnes; Stephen A Boorjian; David W Hillman; Andrew J Vickers; George G Klee; Hans Lilja
Journal:  Prostate       Date:  2019-10-11       Impact factor: 4.104

6.  Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.

Authors:  Andrew Vickers; Angel Cronin; Monique Roobol; Caroline Savage; Mari Peltola; Kim Pettersson; Peter T Scardino; Fritz Schröder; Hans Lilja
Journal:  J Clin Oncol       Date:  2010-04-26       Impact factor: 44.544

7.  A common prostate cancer risk variant 5' of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations.

Authors:  Kevin M Waters; Daniel O Stram; Loic Le Marchand; Robert J Klein; Camilla Valtonen-André; Mari T Peltola; Laurence N Kolonel; Brian E Henderson; Hans Lilja; Christopher A Haiman
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-24       Impact factor: 4.254

8.  Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?

Authors:  Sigrid V Carlsson; Mari T Peltola; Daniel Sjoberg; Fritz H Schröder; Jonas Hugosson; Kim Pettersson; Peter T Scardino; Andrew J Vickers; Hans Lilja; Monique J Roobol
Journal:  BJU Int       Date:  2013-02-28       Impact factor: 5.588

9.  Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations.

Authors:  Christopher A Haiman; Daniel O Stram; Andrew J Vickers; Lynne R Wilkens; Katharina Braun; Camilla Valtonen-André; Mari Peltola; Kim Pettersson; Kevin M Waters; Loic Le Marchand; Laurence N Kolonel; Brian E Henderson; Hans Lilja
Journal:  J Natl Cancer Inst       Date:  2012-12-03       Impact factor: 13.506

10.  Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.

Authors:  Sigrid Carlsson; Alexandra Maschino; Fritz Schröder; Chris Bangma; Ewout W Steyerberg; Theo van der Kwast; Geert van Leenders; Andrew Vickers; Hans Lilja; Monique J Roobol
Journal:  Eur Urol       Date:  2013-05-02       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.